Management Change/Compensation Form 8 K

(e)

On July 22, 2024, Mina Pastagia, M.D. ("Dr. Pastagia") and Armata Pharmaceuticals, Inc. (the "Company") entered into an agreement (the "Amendment"), which amended certain terms of Dr. Pastagia's Employment Agreement with the Company, dated September 22, 2020 (the "Employment Agreement"). The Amendment updates the Employment Agreement to reflect the fact that Dr. Pastagia has been serving as the Company's Chief Medical Officer since January 1, 2023 and that her base salary has been $456,800 since her promotion. Additionally, commencing with the 2024 fiscal year, Dr. Pastagia will have a target annual bonus opportunity equal to 50% of her annual base salary, with the actual bonus payable in respect of any fiscal year dependent on actual performance as determined by the Company's board of directors or compensation committee. Additionally, Dr. Pastagia will be eligible for additional grants pursuant to the Company's 2016 Equity Incentive Plan (or any successor plan) commencing in 2025, with the actual size of any grant to be consistent with her position as the Company's Chief Medical Officer (with the current intent being for any such award to have a grant date fair value equal to $300,000), as determined by the Company's board of directors or compensation committee. In the event that Dr. Pastagia's employment is terminated by the Company without "cause" or if she resigns for "good reason" (in each case as defined in the Employment Agreement), then, subject to her execution of a release and compliance with her post-termination restrictive covenants, she will be entitled to a continuation of her base salary for 12 months following such termination.

The foregoing description does not constitute a complete summary of the terms of the Amendment or the Employment Agreement and is qualified in its entirety by reference to the full text of each of the Amendment and the Employment Agreement, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this report and incorporated by reference herein.